Drug Profile


Alternative Names: 433908; 908; GW-433908; Lexiva; Telzir; VX-175

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer GlaxoSmithKline; Vertex Pharmaceuticals
  • Class Antiretrovirals; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 03 Sep 2015 Fosamprenavir is still in phase II trials for HIV infections (In infants) in the USA, Latin America, Russia, Portugal and South Africa
  • 03 Sep 2015 No recent reports of development identified - Phase-II for HIV infections (In adolescents, In children) in Spain, South Africa, Russia, Romania, Canada, Belgium and USA (PO)
  • 26 Jun 2011 GlaxoSmithKline and ViiV Healthcare complete enrolment in its phase II trial for HIV infections (in infants aged 4 weeks to < 2years) in Argentina, Mexico, Portugal, Puerto Rico, Russia, South Africak and USA (NCT00071760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top